Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 1 symbols : BAX save search
Xenetic Biosciences Announces Positive Phase 1 Clinical Data for PulmoXen(TM) for Treatment of Cystic Fibrosis
Published: 2014-04-07 (Crawled : 07:00) - globenewswire.com
BAX | $40.4 2.36% 0.0% 3.2M
|
Health Technology
| Email alert
Add to watchlist
XBIO | $4.2 7.32% 7.2K
|
Health Technology
| Email alert
Add to watchlist
treatment fibrosis phase 1 positive phase 3 phase 2 cystic fibrosis
Merrimack Pharmaceuticals Announces Initiation of Phase 1 Clinical Study of MM-398 for Brain Cancer
Published: 2014-11-06 (Crawled : 12:20) - globenewswire.com
MACK 4 | $14.75 0.2% 0.2% 95K
|
Health Technology
| Email alert
Add to watchlist
BAX | $40.4 2.36% 0.0% 3.2M
|
Health Technology
| Email alert
Add to watchlist
phase 1 cancer brain cancer phase 3 phase 2 train
Xenetic Biosciences Announces Positive Phase 1 Clinical Results for PSA-Oxyntomodulin for the Treatment of Type II Diabetes and Obesity
Published: 2014-05-12 (Crawled : 00:20) - globenewswire.com
BAX | $40.4 2.36% 0.0% 3.2M
|
Health Technology
| Email alert
Add to watchlist
XBIO | $4.2 7.32% 7.2K
|
Health Technology
| Email alert
Add to watchlist
diabetes treatment obesity phase 1 positive results phase 3 phase 2
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.